Question of the week:

What’s the latest on the MDV 3100 clinical study? 

What is the mode of action of this oral drug?

Video Blog Presentation:

Dr. Celestia Higano will talk about the status of the drug

and info about the Prevail study- MDV 3100 prior to

Chemotherapy.  Includes animation of the mode of  action.

The related article of the week:

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. Epub 2011 Sep 13.  Novel therapies for metastatic castrate-resistant prostate cancer.  Dayyani F, Gallick GE, Logothetis CJ, Corn PG.